The Cooper Companies, Inc. (COO) is a multinational corporation that operates through two business units: CooperVision and CooperSurgical. The company specializes in the development, manufacture, and sale of a range of specialty healthcare products.
CooperVision, the contact lens unit, is one of the world's leading manufacturers of soft contact lenses and related products and services. They develop, manufacture, and market a diverse range of contact lenses, including soft spherical lenses, soft toric lenses, soft multifocal lenses, and other premium contact lenses that are used to correct near- and farsightedness, as well as astigmatism and presbyopia. These products, known for their high quality and advanced technology, are distributed over 100 countries globally. CooperVision continuously invests in innovations and offers a wide selection of contact lenses to meet the unique visual requirements and lifestyle needs of customers worldwide.
On the other hand, CooperSurgical is focused on advancing the health of women, babies, and families with its diverse products and services for the women’s health care sector. The CooperSurgical business segment creates a wide array of medical devices, diagnostic products, and surgical instruments used primarily by obstetricians and gynecologists in their offices, clinics, hospitals, and surgical centers. The products by CooperSurgical range from fertility treatments to devices aiding in high-risk obstetric care which have contributed significantly to maternal and infant health worldwide.
The Cooper Companies, Inc., founded in 1980 and headquartered in San Ramon, California, has established a strong reputation for its commitment to quality, customer satisfaction, and continuous product development. Their innovative spirit, coupled with a focus on empowering people to enjoy a healthier and better life quality, has helped them carve a unique niche for themselves in their respective industries.
Despite a highly dynamic and challenging market environment, the Cooper Companies, Inc. has consistently demonstrated effective strategies, a broad product portfolio, extensive geographical reach, and a well-anchored customer relationship, which have helped to sustain their growth and profitability. The company's focus on meeting healthcare needs through innovative product solutions continues to inspire confidence among its stakeholders, tunneling its vision towards global leadership in improving lives, one person at a time.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
The Cooper Companies (COO) shares have seen a slight increase of 0.2% since its last earnings report, underperforming the S&P 500. For Q3 fiscal 2026, COO beat adjusted EPS estimates but missed revenue expectations, largely due to U.S. CooperVision channel inventory reductions. The company provided its outlook for Q4 and updated guidance for fiscal 2026, with estimates trending downward, leading to a Zacks Rank #5 (Strong Sell).
Lawrence Erik Kurzius, a Director at The Cooper Companies, Inc. (NASDAQ:COO), recently acquired 10,000 shares for $539,100, significantly increasing his direct ownership. This purchase suggests a bullish outlook on the company's future stock performance, despite a recent 19% decline in its share price. Insider buying is often seen as a positive signal to investors, indicating that those with intimate knowledge of the company believe its stock is undervalued.
Walter M. Jr Rosebrough, a Director at The Cooper Companies, Inc. (NASDAQ:COO), recently purchased 10,000 shares for $542,000, significantly increasing his stake in the company. This insider buying is generally seen as a bullish signal, as such moves often precede a rise in stock price, reflecting the insider's confidence in the company's future growth and profitability, especially after a 19% stock decline. The acquisition was made indirectly through a trust and now represents slightly over 0.01% of the company's outstanding common stock.
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into The Cooper Companies, Inc. (COO) following a significant drop in its stock price. The investigation stems from the Company's announcement of disappointing third-quarter 2026 results and reduced full-year guidance due to U.S. channel inventory reductions, which led to a 14.67% decline in shares. Shareholders who suffered losses are urged to contact the law firm to learn about potentially recovering their losses.
The Law Offices of Frank R. Cruz is continuing its investigation into The Cooper Companies, Inc. (COO) for potential federal securities law violations. This follows a significant decline in Cooper Companies' share price after the company reported flat third-quarter revenue, attributed to U.S. channel inventory reductions, and subsequently lowered its full-year guidance. Shareholders who incurred losses are encouraged to contact the firm to inquire about pursuing a claim.